ARVINAS, INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Arvinas secured FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader approved by the FDA, for ER+/HER2−/ESR1-mutated advanced/metastatic breast cancer. The company entered a license agreement with Rigel Pharmaceuticals granting exclusive global development, manufacturing, and commercialization rights. Arvinas recognized $62.5M upfront revenue from the Rigel License Agreement, $50M from an FDA approval milestone payment, and retained $112.6M from deferred Pfizer revenue recognition, for total Q2 2026 revenue of $249.7M vs. $22.4M in Q2 2025. Cash position stood at $567.9M (down from $685.4M at YE 2025, net of $114.3M operating burn YTD), sufficient to fund operations into H2 2028.
Why this rating
Landmark first PROTAC approval validates platform; $112.5M net revenue inflow (Rigel upfront + FDA milestone) represents 24% of company market cap. Reduces near-term cash burn risk. Out-licensing reduces revenue upside but de-risks commercialization. Pipeline still early-stage.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.